Effect of Interleukin-10 and Platelet-derived Growth Factor on Expressions of Matrix Metalloproteinases-2 and Tissue Inhibitor of Metalloproteinases-1 in Rat Fibrotic Liver and Cultured Hepatic Stellate Cells

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2004 Aug 10

PMID 15300910

Citations 5

Authors

Li-Juan Zhang

Yun-Xin Chen

Zhi-Xin Chen

Yue-Hong Huang

Jie-Ping Yu

Xiao-Zhong Wang

Affiliations

Soon will be listed here.

Abstract

Aim: To examine the expressions of matrix metalloproteinases-2 (MMP-2) and tissue inhibitor of metalloproteinases-1 (TIMP-1) in rat fibrotic liver and in normal rat hepatic stellate cells, and to investigate the changes in their expressions in response to treatment with interleukin-10 (IL-10) and platelet-derived growth factor (PDGF).

Methods: Rat models of CCl4-induced hepatic fibrosis were established and the liver tissues were sampled from the rats with or without IL-10 treatment, and also from the control rats. The expressions of MMP-2 and TIMP-1 in liver tissues were detected by S-P immunohistochemistry, and their expression intensities were evaluated in different groups. Hepatic stellate cells (HSCs) were isolated from normal rat and cultured in vitro prior to exposure to PDGF treatment or co-treatment with IL-10 and PDGF. MMP-2 and TIMP-1 levels were measured by semi-quantitative reverse transcriptional polymerase chain reaction (RT-PCR).

Results: CCl4- induced rat hepatic fibrosis models were successfully established. The positive expressions of MMP-2 and TIMP-1 increased obviously with the development of hepatic fibrosis, especially in untreated model group (84.0% and 92.0%, P<0.01). The positive signals decreased significantly following IL-10 treatment (39.3% and 71.4%, P<0.01 and P<0.05) in a time-dependent manner. TIMP-1 mRNA in PDGF-treated group was significantly increased time-dependently in comparison with that of the control group, but PDGF did not obviously affect MMP-2 expression. No difference was noted in TIMP-1 and MMP-2 expressions in HSCs after IL-10 and PDGF treatment (P>0.05).

Conclusion: MMP-2 and TIMP-1 expressions increase in liver tissues with the development of fibrosis, which can be inhibited by exogenous IL-10 inhibitor. PDGF induces the up-regulation of TIMP-1 but not MMP-2 in the HSCs. IL-10 inhibits TIMP-1 and MMP-2 expressions in HSCs induced by PDGF.

Citing Articles

Pathophysiology of chronic pancreatitis induced by dibutyltin dichloride joint ethanol in mice.

Zhang H, Liu B, Xu X, Jiang T, Zhang X, Shi Y World J Gastroenterol. 2016; 22(10):2960-70.

PMID: 26973392 PMC: 4779919. DOI: 10.3748/wjg.v22.i10.2960.

Activation of peroxisome proliferator activated receptor alpha ameliorates ethanol mediated liver fibrosis in mice.

Nan Y, Kong L, Ren W, Wang R, Du J, Li W Lipids Health Dis. 2013; 12:11.

PMID: 23388073 PMC: 3608939. DOI: 10.1186/1476-511X-12-11.

RNA interference targeting the platelet-derived growth factor receptor beta subunit ameliorates experimental hepatic fibrosis in rats.

Chen S, Zhang X, Wang C, Chen W, Xie W, Chen Y Liver Int. 2008; 28(10):1446-57.

PMID: 18466260 PMC: 2710794. DOI: 10.1111/j.1478-3231.2008.01759.x.

Interleukin-10 and chronic liver disease.

Zhang L, Wang X World J Gastroenterol. 2006; 12(11):1681-5.

PMID: 16586534 PMC: 4124340. DOI: 10.3748/wjg.v12.i11.1681.

Therapeutic effect of interleukin-10 on CCl4-induced hepatic fibrosis in rats.

Huang Y, Shi M, Zheng W, Zhang L, Chen Z, Wang X World J Gastroenterol. 2006; 12(9):1386-91.

PMID: 16552806 PMC: 4124315. DOI: 10.3748/wjg.v12.i9.1386.

References

Reeves H, Friedman S . Activation of hepatic stellate cells--a key issue in liver fibrosis. Front Biosci. 2002; 7:d808-26. DOI: 10.2741/reeves. View

Will H, Atkinson S, Butler G, Smith B, Murphy G . The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation. Regulation by TIMP-2 and TIMP-3. J Biol Chem. 1996; 271(29):17119-23. DOI: 10.1074/jbc.271.29.17119. View

Iredale J, Benyon R, Pickering J, McCullen M, Northrop M, Pawley S . Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest. 1998; 102(3):538-49. PMC: 508915. DOI: 10.1172/JCI1018. View

Sakaida I, Uchida K, Hironaka K, Okita K . Prolyl 4-hydroxylase inhibitor (HOE 077) prevents TIMP-1 gene expression in rat liver fibrosis. J Gastroenterol. 1999; 34(3):376-7. DOI: 10.1007/s005350050277. View

Swiderski R, Dencoff J, Floerchinger C, Shapiro S, Hunninghake G . Differential expression of extracellular matrix remodeling genes in a murine model of bleomycin-induced pulmonary fibrosis. Am J Pathol. 1998; 152(3):821-8. PMC: 1858388. View

Kinnman N, Hultcrantz R, Barbu V, Rey C, Wendum D, Poupon R . PDGF-mediated chemoattraction of hepatic stellate cells by bile duct segments in cholestatic liver injury. Lab Invest. 2000; 80(5):697-707. DOI: 10.1038/labinvest.3780073. View

Ziswiler R, Kung M, Marti H . Inhibition of matrix metalloproteinases attenuates anti-Thy1.1 nephritis. J Am Soc Nephrol. 1998; 9(3):397-407. DOI: 10.1681/ASN.V93397. View

Kovalovich K, DeAngelis R, Li W, Furth E, Ciliberto G, TAUB R . Increased toxin-induced liver injury and fibrosis in interleukin-6-deficient mice. Hepatology. 1999; 31(1):149-59. DOI: 10.1002/hep.510310123. View

McCrudden R, Iredale J . Liver fibrosis, the hepatic stellate cell and tissue inhibitors of metalloproteinases. Histol Histopathol. 2000; 15(4):1159-68. DOI: 10.14670/HH-15.1159. View

10.

Neubauer K, Saile B, Ramadori G . Liver fibrosis and altered matrix synthesis. Can J Gastroenterol. 2001; 15(3):187-93. DOI: 10.1155/2001/870205. View

11.

Pinzani M . PDGF and signal transduction in hepatic stellate cells. Front Biosci. 2002; 7:d1720-6. DOI: 10.2741/A875. View

12.

Arthur M, Mann D, Iredale J . Tissue inhibitors of metalloproteinases, hepatic stellate cells and liver fibrosis. J Gastroenterol Hepatol. 1998; 13 Suppl:S33-8. View

13.

Nelson D, Lauwers G, Lau J, Davis G . Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. Gastroenterology. 2000; 118(4):655-60. DOI: 10.1016/s0016-5085(00)70134-x. View

14.

Safadi R, Friedman S . Hepatic fibrosis--role of hepatic stellate cell activation. MedGenMed. 2002; 4(3):27. View

15.

Benyon R, Arthur M . Extracellular matrix degradation and the role of hepatic stellate cells. Semin Liver Dis. 2001; 21(3):373-84. DOI: 10.1055/s-2001-17552. View

16.

Reitamo S, Remitz A, Tamai K, Uitto J . Interleukin-10 modulates type I collagen and matrix metalloprotease gene expression in cultured human skin fibroblasts. J Clin Invest. 1994; 94(6):2489-92. PMC: 330082. DOI: 10.1172/JCI117618. View

17.

Takahara T, Furui K, YATA Y, Jin B, Zhang L, Nambu S . Dual expression of matrix metalloproteinase-2 and membrane-type 1-matrix metalloproteinase in fibrotic human livers. Hepatology. 1997; 26(6):1521-9. DOI: 10.1002/hep.510260620. View

18.

Rockey D . The cell and molecular biology of hepatic fibrogenesis. Clinical and therapeutic implications. Clin Liver Dis. 2001; 4(2):319-55. DOI: 10.1016/s1089-3261(05)70113-6. View

19.

Marra F, Gentilini A, Pinzani M, Choudhury G, Parola M, Herbst H . Phosphatidylinositol 3-kinase is required for platelet-derived growth factor's actions on hepatic stellate cells. Gastroenterology. 1997; 112(4):1297-306. DOI: 10.1016/s0016-5085(97)70144-6. View

20.

Takahara T, Furui K, Funaki J, Nakayama Y, Itoh H, Miyabayashi C . Increased expression of matrix metalloproteinase-II in experimental liver fibrosis in rats. Hepatology. 1995; 21(3):787-95. View